How to buy Adagene (ADAG) stock

Adagene Inc wrapped up its $139.73 million initial public offering, selling 7,354,000 American depositary shares at $19 each. The stock opened at $20.40 when trading began Tuesday and skyrocketed by more than 45% in early trading.

Adagene stock price (NASDAQ: ADAG)

Use our graph to track the performance of ADAG stocks over time.

Adagene shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$14.18
52-week range	$11.11 - $31.83
50-day moving average	$14.77
200-day moving average	$17.01
Wall St. target price	$34.14
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Adagene shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Adagene stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Adagene Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adagene price performance over time

Historical closes compared with the close of $14.18 from 2021-05-28

1 week (2021-07-13)	N/A
1 month (2021-06-24)	1.36%
3 months (2021-04-20)	N/A
6 months (2021-01-20)	N/A

1 year (2020-07-20)	N/A
2 years (2019-07-20)	N/A
3 years (2018-07-20)	N/A
5 years (2016-07-20)	N/A

Adagene financials

Revenue TTM	$700,913
Gross profit TTM	$700,913
Return on assets TTM	-28.37%
Return on equity TTM	-52.26%
Profit margin	0%
Book value	N/A
Market capitalisation	$900 million

TTM: trailing 12 months

Shorting Adagene shares

There are currently 108,339 Adagene shares held short by investors – that's known as Adagene's "short interest". This figure is 63.2% up from 66,366 last month.

There are a few different ways that this level of interest in shorting Adagene shares can be evaluated.

Adagene's "short interest ratio" (SIR)

Adagene's "short interest ratio" (SIR) is the quantity of Adagene shares currently shorted divided by the average quantity of Adagene shares traded daily (recently around 63356.140350877). Adagene's SIR currently stands at 1.71. In other words for every 100,000 Adagene shares traded daily on the market, roughly 1710 shares are currently held short.

To gain some more context, you can compare Adagene's short interest ratio against those of similar companies.

• Novo Nordisk A/S (NVO.US): 5.61
• Regeneron Pharmaceuticals (REGN.US): 1.71
• Alexion Pharmaceuticals (ALXN.US): 5.36

However Adagene's short interest can also be evaluated against the total number of Adagene shares, or, against the total number of tradable Adagene shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adagene's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Adagene shares in existence, roughly 0 shares are currently held short) or 0.006% of the tradable shares (for every 100,000 tradable Adagene shares, roughly 6 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adagene.

Find out more about how you can short Adagene stock.

Adagene share dividends

We're not expecting Adagene to pay a dividend over the next 12 months.

You may also wish to consider:

• Novo Nordisk A/S (NVO.US) (10.25% forward annual dividend yield)

Adagene overview

Adagene Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of various tumors. The company was founded in 2011 and is headquartered in Suzhou, China. .

Frequently asked questions

What percentage of Adagene is owned by institutions?
Currently 17.186% of Adagene shares are held by institutions. How many people work for Adagene?
Latest data suggests 198 work at Adagene. When does the fiscal year end for Adagene?
Adagene's fiscal year ends in December. Where is Adagene based?
Adagene's address is: Building C14, Suzhou, China, 25125